Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RIAZ BABER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1740365808
CMS profile
169404
Location
NAPERVILLE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$90.37

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $90.37 4

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Otsuka America Pharmaceutical, Inc. $50.55 3
JAZZ PHARMACEUTICALS INC. $39.82 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RIAZ BABER

NPI 1740365808 · CMS profile ID 169404

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

NAPERVILLE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740365808?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RIAZ BABER, NPI 1740365808, CMS profile ID 169404. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740365808?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). RIAZ BABER, NPI 1740365808, CMS profile ID 169404. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740365808?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
RIAZ BABER, NPI 1740365808, CMS profile ID 169404, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1740365808?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $90.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
JAZZ PHARMACEUTICALS INC. $39.8212/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951378253 CMS
Otsuka America Pharmaceutical, Inc. $14.9810/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929251979 CMS
Otsuka America Pharmaceutical, Inc. $18.8208/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929251975 CMS
Otsuka America Pharmaceutical, Inc. $16.7506/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929251971 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $17.48 1
PY2021 $25.10 1
PY2022 $90.37 4
PY2023 $52.86 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $341,122.24 185
PY2024 Principal investigator $389,598.32 164
PY2023 Recipient $20,894.00 17
PY2023 Principal investigator $262,289.24 63
PY2022 Recipient $8,539.60 3
PY2022 Principal investigator $221,491.86 60
PY2021 Recipient $40,104.00 15
PY2021 Principal investigator $235,417.23 45
PY2020 Principal investigator $547,839.81 74
PY2019 Recipient $1,141.05 5
PY2019 Principal investigator $378,637.76 82

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

87 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $1,527.15 12/31/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
Phase 4 PMR Pediatric GAD No dispute reported 06/30/2026 670120141
Principal investigator 1 Allergan Inc. $7,399.46 12/31/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration 1-week screeningwashout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 670121381
Principal investigator 1 Allergan Inc. $13,965.95 12/13/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration 1-week screeningwashout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 670111028
Principal investigator 1 Neurocrine Biosciences, Inc. $221.00 12/12/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686568283
Principal investigator 1 H. Lundbeck A S $786.58 12/10/2019 Non-covered Recipient Entity
AMR - BABER RESEARCH
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder MDD From 7 to 18 Years of Age No dispute reported 06/30/2026 681160831
Principal investigator 1 H. Lundbeck A S $23,368.50 12/05/2019 Non-covered Recipient Entity
AMR - BABER RESEARCH
Real-life Effectiveness of Vortioxetine in Depression RELIEVE No dispute reported 06/30/2026 681160746
Principal investigator 1 Neurocrine Biosciences, Inc. $210.07 12/05/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686568195
Principal investigator 1 H. Lundbeck A S $10,681.32 11/28/2019 Non-covered Recipient Entity
AMR - BABER RESEARCH
Active Reference Fluoxetine Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder MDD No dispute reported 06/30/2026 681160581
Principal investigator 1 Allergan Inc. $14,060.95 11/15/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration 1-week screeningwashout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 670098837
Principal investigator 1 H. Lundbeck A S $12,032.56 10/23/2019 Non-covered Recipient Entity
AMR - BABER RESEARCH
Active Reference Fluoxetine Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder MDD No dispute reported 06/30/2026 681160459
Principal investigator 1 Allergan Inc. $225.00 10/22/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. No dispute reported 06/30/2026 670089299
Principal investigator 1 Allergan Inc. $225.00 10/22/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670089344
Principal investigator 1 Allergan Inc. $10,019.65 10/17/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration 1-week screeningwashout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 670087199
Principal investigator 1 Neurocrine Biosciences, Inc. $1.16 10/10/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686567723
Principal investigator 1 Neurocrine Biosciences, Inc. $0.77 10/03/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686567643
Principal investigator 1 Allergan Inc. $7,906.25 09/12/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. No dispute reported 06/30/2026 670074689
Principal investigator 1 Allergan Inc. $11,744.15 09/12/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670074771
Principal investigator 1 Neurocrine Biosciences, Inc. $10,000.00 09/05/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686567313
Principal investigator 1 Neurocrine Biosciences, Inc. $9.67 08/29/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686567211
Principal investigator 1 Allergan Inc. $18,233.35 08/22/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670067679
Principal investigator 1 Neurocrine Biosciences, Inc. $8.87 08/22/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686567181
Principal investigator 1 Neurocrine Biosciences, Inc. $5,202.23 08/01/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686567067
Principal investigator 1 Allergan Inc. $4,610.35 07/23/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670059697
Principal investigator 1 Neurocrine Biosciences, Inc. $1.16 07/18/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686566927
Principal investigator 1 Neurocrine Biosciences, Inc. $0.77 07/11/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686566879
Principal investigator 1 Neurocrine Biosciences, Inc. $2,223.00 06/27/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686566787
Principal investigator 1 Allergan Inc. $10,013.00 06/25/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670053285
Recipient Allergan Inc. $451.88 06/20/2019 Covered Recipient Physician Phase 4 PMR Pediatric GAD No dispute reported 06/30/2026 670005543
Principal investigator 1 Neurocrine Biosciences, Inc. $311.00 06/20/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686566635
Principal investigator 1 Neurocrine Biosciences, Inc. $338.00 06/20/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686566689
Recipient Allergan Inc. $656.70 06/19/2019 Covered Recipient Physician Phase 4 PMR Pediatric GAD No dispute reported 06/30/2026 670005537
Recipient Allergan Inc. $8.62 06/19/2019 Covered Recipient Physician Phase 4 PMR Pediatric GAD No dispute reported 06/30/2026 670005541
Recipient Allergan Inc. $10.21 06/18/2019 Covered Recipient Physician Phase 4 PMR Pediatric GAD No dispute reported 06/30/2026 670005535
Recipient Allergan Inc. $13.64 06/17/2019 Covered Recipient Physician Phase 4 PMR Pediatric GAD No dispute reported 06/30/2026 670005527
Principal investigator 1 Neurocrine Biosciences, Inc. $29,945.50 06/13/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686566479
Principal investigator 1 Neurocrine Biosciences, Inc. $3,479.28 06/13/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
ROLLOVER STUDY FOR CONTINUING NBI-98854 ADMINISTRATION IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686566481
Principal investigator 1 Neurocrine Biosciences, Inc. $221.00 06/13/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH GROUP INC
ROLLOVER STUDY FOR CONTINUING NBI-98854 ADMINISTRATION IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686566509
Principal investigator 1 Neurocrine Biosciences, Inc. $7,122.60 06/06/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686566423
Principal investigator 1 Neurocrine Biosciences, Inc. $2,798.55 06/06/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686566425
Principal investigator 1 Sunovion Pharmaceuticals Inc. $7,066.50 05/17/2019 Non-covered Recipient Entity
AMR-BABAR RESEARCH INC
Pediatric Open-Label Extension Study No dispute reported 06/30/2026 629917487
Principal investigator 1 Sunovion Pharmaceuticals Inc. $8,464.25 05/17/2019 Non-covered Recipient Entity
AMR-BABAR RESEARCH INC
Pediatric Open-Label Extension Study No dispute reported 06/30/2026 631842307
Principal investigator 1 Allergan Inc. $9,116.00 05/14/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670044573
Principal investigator 1 Neurocrine Biosciences, Inc. $1,953.00 05/02/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565935
Principal investigator 1 Neurocrine Biosciences, Inc. $4,631.17 05/02/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565937
Principal investigator 1 Allergan Inc. $13,429.20 04/23/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670039535
Principal investigator 1 Neurocrine Biosciences, Inc. $8,541.00 04/04/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565389
Principal investigator 1 Neurocrine Biosciences, Inc. $4,679.78 04/04/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565391
Principal investigator 1 Neurocrine Biosciences, Inc. $5.65 04/04/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565463
Principal investigator 1 Neurocrine Biosciences, Inc. $5.65 04/04/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565539
Principal investigator 1 Allergan Inc. $1,200.00 04/02/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A PHASE 3, LONG-TERM, OPEN-LABEL STUDY OF SAFETY AND TOLERABILITY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670035509
Principal investigator 1 Allergan Inc. $7,500.00 04/02/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A PHASE 3, LONG-TERM, OPEN-LABEL STUDY OF SAFETY AND TOLERABILITY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670035563
Principal investigator 1 Allergan Inc. $450.00 04/02/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A PHASE 3, LONG-TERM, OPEN-LABEL STUDY OF SAFETY AND TOLERABILITY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670035601
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $5,000.00 04/02/2019 Non-covered Recipient Entity
AMR - BABER RESEARCH INC
A RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE LONGER-TERM IE, MAINTENANCE EFFICACY OF ORAL ARIPIPRAZOLE IN THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE'S DISORDER No dispute reported 06/30/2026 696053925
Principal investigator 1 Neurocrine Biosciences, Inc. $203.00 03/28/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565313
Principal investigator 1 Neurocrine Biosciences, Inc. $743.00 03/21/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565227
Principal investigator 1 Allergan Inc. $3,198.65 03/19/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670031289
Principal investigator 1 Neurocrine Biosciences, Inc. $6,890.40 03/14/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564975
Principal investigator 1 Neurocrine Biosciences, Inc. $5,335.87 03/14/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564977
Principal investigator 1 Neurocrine Biosciences, Inc. $1,899.45 03/14/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
ROLLOVER STUDY FOR CONTINUING NBI-98854 ADMINISTRATION IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564979
Principal investigator 1 Neurocrine Biosciences, Inc. $743.00 03/11/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564923
Principal investigator 1 Allergan Inc. $3,211.00 02/19/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670025695
Principal investigator 1 Neurocrine Biosciences, Inc. $17,497.80 02/07/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564399
Principal investigator 1 Neurocrine Biosciences, Inc. $12,560.40 02/07/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564401
Principal investigator 1 Neurocrine Biosciences, Inc. $7,824.61 02/07/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564403
Principal investigator 1 Neurocrine Biosciences, Inc. $1,547.10 02/07/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
ROLLOVER STUDY FOR CONTINUING NBI-98854 ADMINISTRATION IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564405
Principal investigator 1 Neurocrine Biosciences, Inc. $5.18 01/31/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564199
Principal investigator 1 Neurocrine Biosciences, Inc. $4.51 01/31/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH GROUP INC
ROLLOVER STUDY FOR CONTINUING NBI-98854 ADMINISTRATION IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564203
Principal investigator 1 Neurocrine Biosciences, Inc. $27.56 01/31/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564207
Principal investigator 1 Neurocrine Biosciences, Inc. $5.18 01/31/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564211
Principal investigator 1 Allergan Inc. $1,835.00 01/29/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF VILAZODONE IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670019865
Principal investigator 1 Allergan Inc. $9,819.20 01/15/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670016529
Principal investigator 1 Neurocrine Biosciences, Inc. $8,379.00 01/10/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563537
Principal investigator 1 Neurocrine Biosciences, Inc. $12,845.02 01/10/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563541
Principal investigator 1 Neurocrine Biosciences, Inc. $1,219.05 01/10/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
ROLLOVER STUDY FOR CONTINUING NBI-98854 ADMINISTRATION IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563543
Principal investigator 1 Neurocrine Biosciences, Inc. $5.65 01/10/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563719
Principal investigator 1 Neurocrine Biosciences, Inc. $338.00 01/10/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563725
Principal investigator 1 Allergan Inc. $1,000.00 01/08/2019 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. No dispute reported 06/30/2026 670015611
Principal investigator 1 Neurocrine Biosciences, Inc. $46.00 01/03/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686562793
Principal investigator 1 Neurocrine Biosciences, Inc. $5.65 01/03/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563397
Principal investigator 1 Neurocrine Biosciences, Inc. $64.00 01/03/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563431
Principal investigator 1 Neurocrine Biosciences, Inc. $64.00 01/03/2019 Non-covered Recipient Entity
AMR-BABER RESEARCH GROUP INC
ROLLOVER STUDY FOR CONTINUING NBI-98854 ADMINISTRATION IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563435
Principal investigator 1 Neurocrine Biosciences, Inc. $46.00 01/03/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563449
Principal investigator 1 Neurocrine Biosciences, Inc. $23.50 01/03/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563451
Principal investigator 1 Neurocrine Biosciences, Inc. $2.93 01/03/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563455
Principal investigator 1 Neurocrine Biosciences, Inc. $128.00 01/03/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563459
Principal investigator 1 Neurocrine Biosciences, Inc. $92.00 01/03/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563463
Principal investigator 1 Neurocrine Biosciences, Inc. $92.00 01/03/2019 Non-covered Recipient Entity
BABER RESEARCH GROUP INC
SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563467